查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2109017

生物電子學：市場洞察、競爭格局與市場預測 - 2034 年

Bioelectronic Medicine - Market Insights, Competitive Landscape, and Market Forecast - 2034
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

概述：

  • 全球生物電子醫療市場預計到 2025 年將達到 89 億美元，到 2034 年將達到 216 億美元。
  • 預計在 2026 年至 2034 年的預測期內，該市場將以 10.3% 的複合年成長率成長。這一成長的促進因素包括：用於治療自體免疫疾病的神經免疫調節療法獲得監管部門批准；慢性疼痛、運動障礙和發炎性疾病的盛行率不斷上升；向封閉回路型和人工智慧自適應刺激平台的轉變；以及植入式神經刺激療法的適應症和保險覆蓋範圍的擴大。
  • 以產品細分市場來看，脊髓刺激系統細分市場預計到 2025 年將佔 34% 的佔有率，從而推動生物電子醫學市場的發展。
  • 按應用領域分類，預計慢性疼痛管理領域將引領生物電子醫學市場，到 2025 年將佔 30% 的市場佔有率。
  • 按最終用戶分類，預計到 2025 年，醫院領域將佔 55% 的市場佔有率，從而推動生物電子醫學市場的發展。
  • 截至 2025 年，北美在生物電子醫療市場中佔據最大佔有率，為 44%，但預計到 2034 年，亞太地區將實現最快成長。

生物電子醫學，也稱為神經調控或電療，是指植入式非侵入性醫療設備，透過向周圍神經、脊髓或大腦發送靶向電脈衝來調節神經迴路，從而在不使用藥物的情況下治療慢性疾病。此領域包括：美敦力、波士頓科學、雅培和Nevro公司生產的用於治療慢性疼痛的脊髓刺激（SCS）系統；美敦力、波士頓科學和雅培公司生產的用於治療帕金森氏症和原發性顫抖的深部腦刺激（DBS）系統；A xonics（波士頓科學）和美敦力公司生產的用於治療膀胱和腸道功能障礙的骶神經和脛神經調控系統；Rivanova公司生產的用於治療難治性癲癇和憂鬱症的迷走神經刺激（VNS）系統；Setpoint Medical和Galvani Bioelectronics公司生產的用於治療自體免疫疾病和發炎性疾病的迷走神經刺激系統；以及Neuropace公司生產的用於治療癲癇的響應式封閉回路型神經刺激系統。 Inspire Medical Systems 和 Rivanova 提供的用於治療阻塞型睡眠呼吸中止症症的舌下神經刺激療法；以及 Electrocore 提供的非侵入性經皮經皮走神經刺激療法。該市場的特點是成熟的神經調控療法與新興的神經免疫生物電子療法相互融合，其標誌是美國食品藥物管理局 (FDA) 於 2025 年批准了首個用於治療類風濕性關節炎的植入式迷走神經刺激設備。

生物電子醫學市場的主要促進因素

  • 神經免疫調節的監管有效性得到認可，以及 FDA 於 2025 年授予 SetPoint 系統上市前批准 (PMA)，為自體免疫疾病植入式生物電子設備建立了第一個監管途徑，並為相關適應症樹立了先例。
  • 慢性疼痛、運動障礙和藥物難治性癲癇的盛行率增加，這些疾病僅靠藥物治療無法充分控制。
  • 過渡到封閉回路型、感測、人工智慧自適應神經刺激平台，實現個人化治療並改善長期治療效果。
  • 擴大臨床證據和保險覆蓋範圍，以增加患者獲得植入式神經調節療法治療疼痛、神經系統疾病和泌尿系統疾病的機會。
  • 由於阻塞型睡眠呼吸中止症和膀胱/腸道功能障礙的發生率不斷上升，舌下和薦骨神經調節系統正日益被採用，作為持續性陽壓呼吸器和藥物療法的替代方案。
  • 設備的不斷小型化、電池壽命的延長以及 MRI 相容性指標的加入，擴大了可治療的患者範圍，從而降低了再次干預率。
  • 醫療技術和製藥公司對神經免疫學和生物電子平台的投資正在增加，例如葛蘭素史克和Verily的合資企業Galvani Bioelectronics，以及企業對專業神經調控公司的風險投資。

推動生物電子醫學市場成長的因素

市場促進因素

神經免疫調節的監管功效認證

重塑生物電子醫學市場的一個根本驅動力是神經免疫調節療法獲得監管部門的批准。 2025年7月，美國食品藥物管理局（FDA）授予SetPoint Medical公司的SetPoint系統上市前核准（PMA），這是首個獲準用於自體免疫成人中重度類風濕性關節炎的植入式神經刺激設備，尤其適用於對生物製藥或標靶合成緩解疾病抗風濕藥（DMARDs）反應不足或不耐受的患者。該批准基於主要臨床試驗RESET-RA的結果，這是一項隨機、假手術對照試驗，並為神經免疫生物電子設備建立了監管類風濕性關節炎和上市前批准的先例。這項批准是數十年來對膽鹼能抗發炎路徑研究的成果，證明刺激頸部迷走神經可以活化人體固有的抗發炎和免疫修復機制。 SetPoint系統的核准樹立了先例，降低了相關項目（例如Galvani Bioelectronics的脾神經刺激平台和正在研究用於治療克隆氏症和其他炎症性疾病的迷走神經刺激項目）的監管不確定性，向臨床醫生、保險公司和投資者表明，神經免疫生物電子療法已從研究階段邁向獲批的標準治療方案。神經免疫調節療法的不確定性得到認可，將維持對生物電子醫學的需求，並在整個預測期內重塑目標市場。

慢性疼痛、運動障礙和藥物難治性癲癇的盛行率增加。

慢性疼痛、運動障礙（如帕金森氏症和原發性顫抖）以及藥物難治性癲癇的日益普遍，推動了對構成生物電子醫學市場基礎的成熟神經調控技術的需求。藥物難治性慢性疼痛（如術後腰痛症候群和椎體腰痛）促使美敦力、波士頓科學、雅培和Nevro等公司採用脊髓刺激系統，越來越多的臨床證據表明，這些系統能夠持續緩解疼痛并減少鴉片類藥物的使用，這為保險公司提供了支持。人口老化導致帕金森氏症和原發性顫抖的盛行率上升，進而推動了深部腦部刺激系統的應用。同時，約三分之一的癲癇患者無法僅透過藥物治療控制癲癇發作，因此對迷走神經刺激和反應性神經刺激的需求依然強勁。隨著這些疾病的盛行率增加，患者和臨床醫生尋求替代強化藥物療法的方法，預計在整個預測期內，對疼痛、運動障礙和神經系統疾病的生物電子神經調控技術的需求將持續存在。

市場限制因素

生物電子醫學市場面臨許多相互關聯的限制因素，阻礙其發展。其中最主要的因素是植入式系統和手術的高昂前期成本。這需要對脈衝產生器、導線、手術植入和術後程控進行投資，而且在許多地區，保險公司在批准永久植入前會要求進行預先核准或實驗性刺激。手術植入的侵入性以及感染疾病、導線移位和硬體相關併發症等相關風險限制了其適應症，一些患者和臨床醫生傾向於推遲治療，轉而繼續藥物治療。在美國以外，針對新型療法（尤其是神經免疫迷走神經刺激）的保險報銷和法規核准流程仍處於起步階段，保險覆蓋範圍的製定、編碼規範的完善以及臨床醫生技能的提升都需要時間。此外，電池壽命、定期更換和充電的需求以及MRI相容顯示器的要求等設備相關因素，也給患者和醫療保健系統帶來了持續的負擔。能夠培訓臨床醫生、進行植入手術和長期程控的專業神經調控和神經免疫中心的發展仍然集中在大型大學醫院和轉診中心，這限制了資源匱乏地區和農村地區的醫療服務取得。這些因素共同減緩了技術的普及速度，供應商需要證明其產品的長期安全性、成本效益以及簡化的植入手術和程控流程，才能維持市場成長。

目錄

第1章：生物電子醫學市場：引言

  • 調查範圍
  • 市場區隔
  • 市場概覽

第2章：生物電子醫學市場：執行摘要

  • 主要亮點和市場概覽

第3章：生物電子醫學市場：關鍵因素分析

  • 市場促進因素
    • 神經免疫調節監管有效性的確認
    • 慢性疼痛、運動障礙和藥物難治性癲癇的盛行率增加。
    • 向封閉回路型和人工智慧自適應神經刺激過渡
    • 擴大臨床證據範圍並開發保險報銷途徑
  • 市場限制因素
    • 植入式系統的初始成本高且侵入性大
    • 神經免疫疾病保險報銷之路仍在發展中。
    • 專業植入中心集中
  • 市場機遇
    • 在神經免疫學領域的擴展應用
    • 封閉回路型和人工智慧自適應平台

第4章：人工智慧、地緣政治、貿易與經濟趨勢

第5章：監理分析

  • 美國
  • 歐洲
  • 日本
  • 中國

第6章：波特五力分析

第7章：生物電子醫學市場：評估

  • 依產品
    • 脊髓刺激系統
    • 深部腦部刺激系統
    • 骶神經和脛神經調節系統
    • 迷走神經刺激系統
    • 響應式封閉回路型神經刺激
    • 舌下神經刺激系統
    • 其他周邊設備及非侵入式生物電子設備
  • 透過使用
    • 慢性疼痛的管理
    • 運動障礙
    • 泌尿和排便功能障礙
    • 阻塞型睡眠呼吸中止症症
    • 癲癇
    • 憂鬱症與精神疾病
    • 發炎性疾病與自體免疫疾病
    • 其他
  • 最終用戶
    • 醫院
    • 門診手術中心
    • 神經科和疼痛專科診所
  • 按地區
    • 北美洲
    • 歐洲
    • 亞太地區
    • 世界其他地區

第8章：生物電子醫學市場：競爭格局

  • 競爭分析
  • 企業市場占有率分析（加值服務）

第9章：生物電子醫學市場：新創企業資金籌措與投資趨勢

第10章：生物電子醫學市場：公司概況與產品概況

  • Medtronic plc
  • Boston Scientific Corporation
  • Abbott Laboratories
  • LivaNova PLC
  • Nevro Corp.
  • NeuroPace, Inc.
  • Inspire Medical Systems, Inc.
  • SetPoint Medical Corporation
  • electroCore, Inc.
  • Saluda Medical Pty Ltd

第11章：KOL的觀點

第12章：專案式教學方法

第13章：關於 DelveInsight

第14章 免責聲明與聯絡方式

Product Code: DIMDCL0961

Bioelectronic Medicine Market Summary

Overview:

  • The global bioelectronic medicine market was valued at USD 8.9 billion in 2025 and is projected to reach USD 21.6 billion by 2034.
  • The market is expected to expand at a CAGR of 10.3% during the forecast period 2026-2034, supported by regulatory validation of neuroimmune modulation for autoimmune disease, the rising prevalence of chronic pain, movement, and inflammatory disorders, the shift toward closed-loop and AI-adaptive stimulation platforms, and the expanding indications and reimbursement pathways for implantable neurostimulation.
  • By product, the spinal cord stimulation systems segment dominated the bioelectronic medicine market with a 34% share in 2025.
  • By application, the chronic pain management segment dominated the bioelectronic medicine market with a 30% share in 2025.
  • By end-user, the hospitals segment dominated the bioelectronic medicine market with a 55% share in 2025.
  • North America accounted for the largest share of the bioelectronic medicine market at 44% in 2025, while Asia-Pacific is anticipated to register the fastest growth through 2034.

Bioelectronic medicine, also referred to as neuromodulation or electroceutical therapy, refers to implantable and non-invasive devices that deliver targeted electrical impulses to peripheral nerves, the spinal cord, or the brain to modulate neural circuits and treat chronic disease without pharmaceuticals. The scope encompasses spinal cord stimulation (SCS) systems for chronic pain from Medtronic, Boston Scientific, Abbott, and Nevro; deep brain stimulation (DBS) systems for Parkinson's disease and essential tremor from Medtronic, Boston Scientific, and Abbott; sacral and tibial neuromodulation systems for bladder and bowel dysfunction from Axonics (Boston Scientific) and Medtronic; vagus nerve stimulation (VNS) systems for drug-resistant epilepsy and depression from LivaNova, and for autoimmune and inflammatory disease from SetPoint Medical and Galvani Bioelectronics; responsive closed-loop neurostimulation for epilepsy from NeuroPace; hypoglossal nerve stimulation for obstructive sleep apnea from Inspire Medical Systems and LivaNova; and non-invasive transcutaneous vagus nerve stimulation from electroCore. The market is defined by the convergence of established neuromodulation categories with the emerging class of neuroimmune bioelectronic therapies, marked by the 2025 FDA approval of the first implanted vagus nerve stimulator for rheumatoid arthritis.

Bioelectronic Medicine Market Key Growth Drivers

  • Regulatory validation of neuroimmune modulation, with the 2025 FDA premarket approval of the SetPoint System establishing the first regulatory pathway for an implanted bioelectronic device in autoimmune disease and opening a precedent for adjacent indications.
  • Rising prevalence of chronic pain, movement disorders, and drug-resistant epilepsy that are inadequately controlled by pharmacological therapy alone.
  • Shift toward closed-loop, sensing-enabled, and AI-adaptive neurostimulation platforms that personalize therapy and improve long-term outcomes.
  • Expanding clinical evidence and reimbursement pathways that broaden patient access to implantable neuromodulation across pain, neurological, and urological indications.
  • Growing incidence of obstructive sleep apnea and bladder and bowel dysfunction driving adoption of hypoglossal and sacral neuromodulation systems as alternatives to continuous positive airway pressure and pharmacological management.
  • Sustained device miniaturization, extended battery life, and MRI-conditional labeling that broaden patient eligibility and reduce reintervention rates.
  • Increasing investment from medical technology companies and pharmaceutical companies in neuroimmune and bioelectronic platforms, exemplified by the GSK-Verily joint venture Galvani Bioelectronics and corporate venture investment in specialist neuromodulation companies.

Key Companies in Bioelectronic Medicine Market

The leading participants in the bioelectronic medicine market include the following:

  • Medtronic plc
  • Boston Scientific Corporation
  • Abbott Laboratories
  • LivaNova PLC
  • Nevro Corp.
  • NeuroPace, Inc.
  • Inspire Medical Systems, Inc.
  • SetPoint Medical Corporation
  • electroCore, Inc.
  • Saluda Medical Pty Ltd

Factors Contributing to the Growth of the Bioelectronic Medicine Market

Market Drivers

Regulatory Validation of Neuroimmune Modulation

The foundational driver reshaping the bioelectronic medicine market is the regulatory validation of neuroimmune modulation as a treatment modality. In July 2025, the FDA granted premarket approval to the SetPoint System from SetPoint Medical, the first implanted neurostimulation device approved for an autoimmune indication, specifically moderate-to-severe rheumatoid arthritis in adults who have had an inadequate response to, or cannot tolerate, biologic or targeted synthetic disease-modifying antirheumatic drugs. The approval was supported by the pivotal RESET-RA trial, a randomized, sham-controlled study, and establishes a regulatory pathway and a body of premarket approval precedent for neuroimmune bioelectronic devices. This approval follows decades of research into the cholinergic anti-inflammatory pathway, which established that stimulating the cervical vagus nerve activates the body's innate anti-inflammatory and immune-restorative mechanisms. The precedent set by the SetPoint System approval reduces regulatory uncertainty for adjacent programs, including Galvani Bioelectronics' splenic nerve stimulation platform and vagus nerve stimulation programs under investigation for Crohn's disease and other inflammatory conditions, and it signals to clinicians, payers, and investors that neuroimmune bioelectronic therapy has moved from investigational science to an approved standard of care option. The regulatory validation of neuroimmune modulation sustains demand and reshapes the addressable market for bioelectronic medicine across the forecast period.

Rising Prevalence of Chronic Pain, Movement Disorders, and Drug-Resistant Epilepsy

The rising prevalence of chronic pain, movement disorders such as Parkinson's disease and essential tremor, and drug-resistant epilepsy sustains demand for established neuromodulation categories that anchor the bioelectronic medicine market. Chronic pain that is refractory to pharmacological management, including failed back surgery syndrome and vertebrogenic low back pain, drives adoption of spinal cord stimulation systems from Medtronic, Boston Scientific, Abbott, and Nevro, and the growing clinical evidence base for durable pain relief and opioid-sparing outcomes reinforces payer support. The aging of the population increases the prevalence of Parkinson's disease and essential tremor, driving adoption of deep brain stimulation systems, while roughly one in three patients with epilepsy do not achieve seizure control with medication alone, sustaining demand for vagus nerve stimulation and responsive neurostimulation. As the prevalence of these conditions grows and as patients and clinicians seek alternatives to escalating pharmacological regimens, demand for bioelectronic neuromodulation across pain, movement, and neurological indications is sustained across the forecast period.

Market Restraints

The bioelectronic medicine market faces several interrelated restraints that temper its growth. The foremost is the high upfront cost of implantable systems and procedures, which require investment in the pulse generator, leads, surgical implantation, and follow-up programming, and payers in many geographies apply prior authorization and trial-stimulation requirements before approving permanent implantation. The invasiveness of surgical implantation and the associated risks of infection, lead migration, and hardware-related complications limit candidacy and drive some patients and clinicians to defer therapy in favor of continued pharmacological management. Reimbursement and regulatory pathways for the newest categories, particularly neuroimmune vagus nerve stimulation, remain in the early stages of establishment outside the United States, and coverage determinations, coding, and clinician familiarity will take time to mature. Device-related considerations, including battery longevity, the need for periodic replacement or recharging, and MRI-conditional labeling requirements, add ongoing burden for patients and health systems. Clinician training and the availability of specialized neuromodulation and neuroimmunology centers capable of implantation and long-term programming remain concentrated in leading academic and referral centers, constraining access in lower-resource and rural settings. Together, these factors moderate the pace of adoption and require vendors to demonstrate long-term safety, cost-effectiveness, and streamlined implantation and programming workflows to sustain growth.

Bioelectronic Medicine Market Segment Analysis

The global bioelectronic medicine market is segmented by product (spinal cord stimulation systems, deep brain stimulation systems, sacral and tibial neuromodulation systems, vagus nerve stimulation systems, responsive and closed-loop neurostimulation, hypoglossal nerve stimulation systems, and other peripheral and non-invasive bioelectronic devices), by application (chronic pain management, movement disorders, urinary and bowel dysfunction, obstructive sleep apnea, epilepsy, depression and psychiatric disorders, inflammatory and autoimmune disease, and others), by end-user (hospitals, ambulatory surgical centers, specialty neurology and pain clinics, and others), and by geography (North America, Europe, Asia-Pacific, and the Rest of the World).

By Product

Dominant Subsegment: Spinal Cord Stimulation Systems.

The spinal cord stimulation systems category is expected to dominate the market. The spinal cord stimulation segment accounted for a 34% share of the bioelectronic medicine market in 2025. Spinal cord stimulation systems, including the Medtronic Intellis and Inceptiv platforms, the Boston Scientific Precision and WaveWriter platforms, the Abbott Proclaim platform, the Nevro Senza platform, and the Saluda Medical Evoke closed-loop platform, are the leading product category because chronic pain is the largest single indication addressed by implantable neurostimulation and because the category benefits from the deepest and longest-established clinical evidence base and reimbursement coverage among bioelectronic therapies. The dominance of the segment reflects the breadth of competing platforms from the largest medical technology companies, the extension of indications to vertebrogenic low back pain and painful diabetic neuropathy, and the ongoing shift toward rechargeable, MRI-conditional, and closed-loop dosing systems. While deep brain stimulation, sacral and tibial neuromodulation, vagus nerve stimulation, and hypoglossal nerve stimulation are substantial and, in the case of neuroimmune vagus nerve stimulation, faster-growing categories, the scale, competitive depth, and reimbursement maturity of spinal cord stimulation sustain the leadership of the segment across the forecast period.

By Application

Dominant Subsegment: Chronic Pain Management.

The chronic pain management category is expected to dominate the market. The chronic pain management segment accounted for a 30% share of the bioelectronic medicine market in 2025. Chronic pain, including failed back surgery syndrome, complex regional pain syndrome, vertebrogenic low back pain, and painful diabetic neuropathy, is the leading application because it affects a substantial share of adults and because spinal cord stimulation and emerging peripheral nerve stimulation platforms, including the Neuros Medical Altius system, provide durable, opioid-sparing symptom control supported by extensive clinical evidence. The dominance of the segment reflects the size of the eligible patient population, the maturity of reimbursement coverage for spinal cord stimulation across major markets, and the policy emphasis on non-pharmacological pain management amid concern over opioid dependence. While movement disorders, urinary and bowel dysfunction, obstructive sleep apnea, epilepsy, and inflammatory and autoimmune disease are significant and, in several cases, faster-growing applications, the scale and reimbursement depth of chronic pain management sustain the leadership of the segment across the forecast period.

Bioelectronic Medicine Market Region Analysis

Dominant Region: North America

North America accounted for a 44% share of the global bioelectronic medicine market in 2025, representing the highest regional market share globally. The leadership of the region reflects the concentration of the leading device manufacturers, the depth of FDA premarket approval activity, the advanced reimbursement coverage of neuromodulation therapies under Medicare and commercial payers, and the presence of the leading academic epilepsy, movement disorder, and pain centers. The United States is the largest national market, anchored by the 2025 FDA approval of the first neuroimmune vagus nerve stimulation device, the concentration of Medtronic, Boston Scientific, Abbott, Nevro, LivaNova, NeuroPace, Inspire Medical Systems, and SetPoint Medical commercial and research operations, and comprehensive coverage policies for spinal cord stimulation, deep brain stimulation, and sacral neuromodulation. The regulatory leadership, reimbursement maturity, and concentration of vendors and specialist centers reinforce the position of North America as the largest regional market across the forecast period.

Fastest Growing Region: Asia-Pacific

Asia-Pacific is projected to register the fastest compound annual growth rate through 2034. The region is expanding and modernizing its neurology, pain management, and urology infrastructure, increasing diagnosis rates for chronic pain, epilepsy, and movement disorders, and adopting spinal cord stimulation, deep brain stimulation, and sacral neuromodulation from a growing base. China, Japan, and India are the principal national markets, supported by the construction and modernization of hospitals, the expansion of neurosurgical and pain management specialist training, the aging of the population, and increasing awareness of bioelectronic alternatives to long-term pharmacological management. As hospitals build specialist neuromodulation programs and as awareness of bioelectronic therapy increases, the region increases its adoption of bioelectronic devices from a growing base, positioning Asia-Pacific as the fastest-growing regional market and attracting commercial investment from the leading global vendors.

Regional Commentary

North America

North America leads the market, supported by the concentration of leading vendors, the depth of FDA regulatory activity and premarket approvals, and advanced reimbursement coverage for neuromodulation therapies. The United States dominates the region through its concentration of device manufacturers and specialist implant centers and through the 2025 approval of the first neuroimmune bioelectronic therapy.

Europe

Europe is a substantial market shaped by CE marking and national health technology assessment pathways, established reimbursement for spinal cord stimulation and deep brain stimulation, and the presence of vendors including Medtronic, Boston Scientific, Abbott, LivaNova, and Saluda Medical. Germany, the United Kingdom, France, Italy, and Spain are the principal national markets, and Galvani Bioelectronics' clinical programs for inflammatory disease are anchored in the region.

Asia-Pacific

Asia-Pacific is the fastest-growing region, driven by hospital modernization, the expansion of specialist neuromodulation and pain management centers, and the growth of the diagnosed patient population for chronic pain, epilepsy, and movement disorders across China, Japan, and India.

Rest of World

The Rest of World, spanning Latin America, the Middle East, and Africa, represents an emerging opportunity as specialist neurology, pain management, and urology infrastructure expands, though adoption varies by market and remains concentrated in leading private and academic hospitals.

Bioelectronic Medicine Market Competitive Landscape

The global bioelectronic medicine market is classified as Moderately Consolidated. A group of diversified medical technology companies holds a substantial share of the market through comprehensive neuromodulation portfolios spanning spinal cord stimulation, deep brain stimulation, and sacral neuromodulation, while specialist vendors compete on differentiated single-category platforms in vagus nerve stimulation, responsive neurostimulation, hypoglossal nerve stimulation, and neuroimmune bioelectronic therapy. Competition centers on the breadth of the neuromodulation portfolio, closed-loop and AI-adaptive stimulation capability, MRI-conditional labeling and device longevity, clinical evidence and reimbursement coverage, and the regulatory head start established by the first approved neuroimmune indication. The competitive landscape is evaluated across the following dimensions:

  • Market concentration: Moderately consolidated, with Medtronic, Boston Scientific, and Abbott holding a substantial share across spinal cord stimulation, deep brain stimulation, and sacral neuromodulation, alongside specialist vendors including Nevro, LivaNova, NeuroPace, Inspire Medical Systems, SetPoint Medical, electroCore, and Saluda Medical.
  • Leading players: Medtronic, Boston Scientific, and Abbott lead across multiple neuromodulation categories; Nevro leads in dedicated spinal cord stimulation, LivaNova leads in vagus nerve stimulation for epilepsy and depression, Inspire Medical Systems leads in hypoglossal nerve stimulation, and SetPoint Medical leads the newly established neuroimmune vagus nerve stimulation category.
  • Geographic reach: The leading diversified medical technology companies operate global commercial and regulatory organizations, while specialist vendors including SetPoint Medical, electroCore, and Saluda Medical maintain more concentrated geographic footprints centered on the United States and Europe.
  • Product portfolio strength: Competitive advantage rests on the breadth across spinal cord stimulation, deep brain stimulation, sacral and tibial neuromodulation, vagus nerve stimulation, and hypoglossal nerve stimulation, and on closed-loop sensing and adaptive stimulation capability.
  • Pipeline strength: Development is concentrated in closed-loop and AI-adaptive stimulation, neuroimmune vagus nerve stimulation for additional autoimmune and inflammatory indications, and miniaturized, longer-lived implantable platforms.
  • Strategic partnerships: Collaboration spans the GSK-Verily Galvani Bioelectronics joint venture, the 2025 Galvani-Johnson & Johnson collaboration on graphene-based vagus nerve therapies, and clinical research partnerships with academic centers including the Feinstein Institutes for Medical Research.
  • M&A activity: Consolidation has shaped the field, exemplified by Boston Scientific's 2024 acquisition of Axonics for sacral neuromodulation and its acquisition of Relievant Medsystems for vertebrogenic pain, alongside continued corporate venture investment in neuroimmune bioelectronic startups.
  • Innovation focus: Innovation is concentrated in closed-loop and sensing-enabled stimulation, exemplified by Medtronic's adaptive Percept platform and Saluda Medical's evoked-response spinal cord stimulation, and in the expansion of neuroimmune vagus nerve stimulation to additional inflammatory indications.
  • Regulatory standing: FDA premarket approval, CE marking, and alignment with the classification and safety guidance of the International Neuromodulation Society and the North American Neuromodulation Society are decisive competitive credentials, with the 2025 SetPoint System approval representing a landmark regulatory precedent.

Bioelectronic Medicine Market Recent Developmental Activities

  • In July 2025, the FDA granted premarket approval to SetPoint Medical's SetPoint System, the first implanted neuroimmune modulation device approved for moderate-to-severe rheumatoid arthritis. Strategic significance: the approval established the first regulatory pathway for a neuroimmune bioelectronic device and set a precedent for adjacent autoimmune and inflammatory indications.
  • In 2024, Boston Scientific completed its acquisition of Axonics, Inc. for approximately USD 3.7 billion, expanding its sacral neuromodulation portfolio for urinary and bowel dysfunction. Strategic significance: the acquisition reinforced Boston Scientific's position across multiple bioelectronic categories and consolidated the sacral neuromodulation segment.

Bioelectronic Medicine Market Segmentation

Bioelectronic Medicine Market Assessment by Product

  • Spinal Cord Stimulation Systems
  • Deep Brain Stimulation Systems
  • Sacral and Tibial Neuromodulation Systems
  • Vagus Nerve Stimulation Systems (Neurological and Neuroimmune)
  • Responsive and Closed-Loop Neurostimulation
  • Hypoglossal Nerve Stimulation Systems
  • Other Peripheral and Non-Invasive Bioelectronic Devices

Bioelectronic Medicine Market Assessment by Application

  • Chronic Pain Management
  • Movement Disorders (Parkinson's Disease and Essential Tremor)
  • Urinary and Bowel Dysfunction
  • Obstructive Sleep Apnea
  • Epilepsy
  • Depression and Psychiatric Disorders
  • Inflammatory and Autoimmune Disease
  • Others

Bioelectronic Medicine Market Assessment by End-User

  • Hospitals
  • Ambulatory Surgical Centers
  • Specialty Neurology and Pain Clinics
  • Others

Bioelectronic Medicine Market Assessment by Geography

  • North America
  • United States Bioelectronic Medicine Market Size in USD million (2023-2034)
  • Canada Bioelectronic Medicine Market Size in USD million (2023-2034)
  • Mexico Bioelectronic Medicine Market Size in USD million (2023-2034)
  • Europe
  • Germany Bioelectronic Medicine Market Size in USD million (2023-2034)
  • United Kingdom Bioelectronic Medicine Market Size in USD million (2023-2034)
  • France Bioelectronic Medicine Market Size in USD million (2023-2034)
  • Italy Bioelectronic Medicine Market Size in USD million (2023-2034)
  • Spain Bioelectronic Medicine Market Size in USD million (2023-2034)
  • Rest of Europe Bioelectronic Medicine Market Size in USD million (2023-2034)
  • Asia-Pacific
  • China Bioelectronic Medicine Market Size in USD million (2023-2034)
  • Japan Bioelectronic Medicine Market Size in USD million (2023-2034)
  • India Bioelectronic Medicine Market Size in USD million (2023-2034)
  • Australia Bioelectronic Medicine Market Size in USD million (2023-2034)
  • South Korea Bioelectronic Medicine Market Size in USD million (2023-2034)
  • Rest of Asia-Pacific Bioelectronic Medicine Market Size in USD million (2023-2034)
  • Rest of the World
  • Middle East Bioelectronic Medicine Market Size in USD million (2023-2034)
  • Africa Bioelectronic Medicine Market Size in USD million (2023-2034)
  • South America Bioelectronic Medicine Market Size in USD million (2023-2034)

Key Takeaways from the Bioelectronic Medicine Market Report Study

  • Market size analysis for the current bioelectronic medicine market size (2025), and market forecast for 9 years (2026 to 2034).
  • Top key product and technology developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years, including the 2025 FDA approval of the first neuroimmune bioelectronic device.
  • Key companies dominating the global bioelectronic medicine market.
  • Various opportunities available for competitors in the bioelectronic medicine market space, including closed-loop stimulation and neuroimmune indication expansion.
  • What are the top-performing segments in 2025? How will these segments perform in 2034?
  • Which are the top-performing regions and countries in the current bioelectronic medicine market scenario?
  • Which are the regions and countries where companies should concentrate their opportunities for bioelectronic medicine market growth in the future?

Target audience who can benefit from this bioelectronic medicine market report study

  • Bioelectronic medicine, neuromodulation, and medical device providers
  • Research organizations and consulting companies
  • Neurology, pain management, urology, and rheumatology-related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and traders dealing in bioelectronic medicine devices
  • Various end-users who want to know more about the bioelectronic medicine market and the latest technological developments in the bioelectronic medicine market.

Frequently Asked Questions:

Q1. At what rate is the bioelectronic medicine market expected to grow?

The global bioelectronic medicine market is projected to grow at a compound annual growth rate of 10.3% during the forecast period from 2026 to 2034.

Q2. What is the current and projected size of the bioelectronic medicine market?

The global bioelectronic medicine market was valued at USD 8.9 billion in 2025 and is projected to reach USD 21.6 billion by 2034.

Q3. Which region dominates the bioelectronic medicine market?

North America dominated the bioelectronic medicine market with a 44% share in 2025, driven by the concentration of leading vendors, FDA regulatory leadership, and advanced reimbursement coverage. Asia-Pacific is projected to record the fastest compound annual growth rate through 2034, driven by hospital modernization and the expansion of specialist neuromodulation infrastructure across China, Japan, and India.

Q4. What are the key factors driving growth in the bioelectronic medicine market?

The principal drivers are the regulatory validation of neuroimmune modulation following the 2025 FDA approval of the first bioelectronic device for rheumatoid arthritis; the rising prevalence of chronic pain, movement disorders, and drug-resistant epilepsy; the shift toward closed-loop and AI-adaptive neurostimulation; expanding clinical evidence and reimbursement pathways; and the growing incidence of obstructive sleep apnea and bladder and bowel dysfunction.

Q5. Who are the major players in the bioelectronic medicine market?

The market is moderately consolidated and led by Medtronic plc, Boston Scientific Corporation, and Abbott Laboratories, alongside LivaNova PLC, Nevro Corp., NeuroPace, Inc., Inspire Medical Systems, Inc., SetPoint Medical Corporation, electroCore, Inc., and Saluda Medical Pty Ltd. Additional participants including Galvani Bioelectronics, Neuros Medical, Cala Health, and ONWARD Medical compete across neuroimmune, peripheral nerve, and spinal cord stimulation.

Table of Contents

1. Bioelectronic Medicine Market Introduction

  • 1.1. Scope of the Report
  • 1.2. Market Segmentation
  • 1.3. Market Overview at a Glance

2. Bioelectronic Medicine Market Executive Summary

  • 2.1. Key Highlights and Market Snapshot

3. Bioelectronic Medicine Market Key Factors Analysis

  • 3.1. Market Drivers
    • 3.1.1. Regulatory Validation of Neuroimmune Modulation
    • 3.1.2. Rising Prevalence of Chronic Pain, Movement Disorders, and Drug-Resistant Epilepsy
    • 3.1.3. Shift toward Closed-Loop and AI-Adaptive Neurostimulation
    • 3.1.4. Expanding Clinical Evidence and Reimbursement Pathways
  • 3.2. Market Restraints
    • 3.2.1. High Upfront Cost and Invasiveness of Implantable Systems
    • 3.2.2. Nascent Reimbursement Pathways for Neuroimmune Indications
    • 3.2.3. Concentration of Specialist Implant Centers
  • 3.3. Market Opportunities
    • 3.3.1. Neuroimmune Indication Expansion
    • 3.3.2. Closed-Loop and AI-Adaptive Platforms

4. Impact Analysis: AI, Geopolitical, Trade, and Economic Developments

5. Regulatory Analysis

  • 5.1. The United States
  • 5.2. Europe
  • 5.3. Japan
  • 5.4. China

6. Bioelectronic Medicine Market Porter's Five Forces Analysis

  • 6.1. Bargaining Power of Suppliers
  • 6.2. Bargaining Power of Consumers
  • 6.3. Threat of New Entrants
  • 6.4. Threat of Substitutes
  • 6.5. Competitive Rivalry

7. Bioelectronic Medicine Market Assessment

  • 7.1. By Product
    • 7.1.1. Spinal Cord Stimulation Systems
    • 7.1.2. Deep Brain Stimulation Systems
    • 7.1.3. Sacral and Tibial Neuromodulation Systems
    • 7.1.4. Vagus Nerve Stimulation Systems
    • 7.1.5. Responsive and Closed-Loop Neurostimulation
    • 7.1.6. Hypoglossal Nerve Stimulation Systems
    • 7.1.7. Other Peripheral and Non-Invasive Bioelectronic Devices
  • 7.2. By Application
    • 7.2.1. Chronic Pain Management
    • 7.2.2. Movement Disorders
    • 7.2.3. Urinary and Bowel Dysfunction
    • 7.2.4. Obstructive Sleep Apnea
    • 7.2.5. Epilepsy
    • 7.2.6. Depression and Psychiatric Disorders
    • 7.2.7. Inflammatory and Autoimmune Disease
    • 7.2.8. Others
  • 7.3. By End-User
    • 7.3.1. Hospitals
    • 7.3.2. Ambulatory Surgical Centers
    • 7.3.3. Specialty Neurology and Pain Clinics
    • 7.3.4. Others
  • 7.4. By Geography
    • 7.4.1. North America
      • 7.4.1.1. United States Bioelectronic Medicine Market Size in USD million (2023-2034)
      • 7.4.1.2. Canada Bioelectronic Medicine Market Size in USD million (2023-2034)
      • 7.4.1.3. Mexico Bioelectronic Medicine Market Size in USD million (2023-2034)
    • 7.4.2. Europe
      • 7.4.2.1. Germany Bioelectronic Medicine Market Size in USD million (2023-2034)
      • 7.4.2.2. United Kingdom Bioelectronic Medicine Market Size in USD million (2023-2034)
      • 7.4.2.3. France Bioelectronic Medicine Market Size in USD million (2023-2034)
      • 7.4.2.4. Italy Bioelectronic Medicine Market Size in USD million (2023-2034)
      • 7.4.2.5. Spain Bioelectronic Medicine Market Size in USD million (2023-2034)
      • 7.4.2.6. Rest of Europe Bioelectronic Medicine Market Size in USD million (2023-2034)
    • 7.4.3. Asia-Pacific
      • 7.4.3.1. China Bioelectronic Medicine Market Size in USD million (2023-2034)
      • 7.4.3.2. Japan Bioelectronic Medicine Market Size in USD million (2023-2034)
      • 7.4.3.3. India Bioelectronic Medicine Market Size in USD million (2023-2034)
      • 7.4.3.4. Australia Bioelectronic Medicine Market Size in USD million (2023-2034)
      • 7.4.3.5. South Korea Bioelectronic Medicine Market Size in USD million (2023-2034)
      • 7.4.3.6. Rest of Asia-Pacific Bioelectronic Medicine Market Size in USD million (2023-2034)
    • 7.4.4. Rest of the World
      • 7.4.4.1. Middle East Bioelectronic Medicine Market Size in USD million (2023-2034)
      • 7.4.4.2. Africa Bioelectronic Medicine Market Size in USD million (2023-2034)
      • 7.4.4.3. South America Bioelectronic Medicine Market Size in USD million (2023-2034)

8. Bioelectronic Medicine Market Competitive Landscape

  • 8.1. Competitive Analysis
  • 8.2. Company Share Analysis (Premium Offering)

9. Bioelectronic Medicine Market Startup Funding and Investment Trends

10. Bioelectronic Medicine Market Company and Product Profiles

  • 10.1. Medtronic plc
    • 10.1.1. Company Overview
    • 10.1.2. Company Snapshot
    • 10.1.3. Financial Overview
    • 10.1.4. Product Portfolio
    • 10.1.5. Strategic Initiatives / Entropy
  • 10.2. Boston Scientific Corporation
    • 10.2.1. Company Overview
    • 10.2.2. Company Snapshot
    • 10.2.3. Financial Overview
    • 10.2.4. Product Portfolio
    • 10.2.5. Strategic Initiatives / Entropy
  • 10.3. Abbott Laboratories
    • 10.3.1. Company Overview
    • 10.3.2. Company Snapshot
    • 10.3.3. Financial Overview
    • 10.3.4. Product Portfolio
    • 10.3.5. Strategic Initiatives / Entropy
  • 10.4. LivaNova PLC
    • 10.4.1. Company Overview
    • 10.4.2. Company Snapshot
    • 10.4.3. Financial Overview
    • 10.4.4. Product Portfolio
    • 10.4.5. Strategic Initiatives / Entropy
  • 10.5. Nevro Corp.
    • 10.5.1. Company Overview
    • 10.5.2. Company Snapshot
    • 10.5.3. Financial Overview
    • 10.5.4. Product Portfolio
    • 10.5.5. Strategic Initiatives / Entropy
  • 10.6. NeuroPace, Inc.
    • 10.6.1. Company Overview
    • 10.6.2. Company Snapshot
    • 10.6.3. Financial Overview
    • 10.6.4. Product Portfolio
    • 10.6.5. Strategic Initiatives / Entropy
  • 10.7. Inspire Medical Systems, Inc.
    • 10.7.1. Company Overview
    • 10.7.2. Company Snapshot
    • 10.7.3. Financial Overview
    • 10.7.4. Product Portfolio
    • 10.7.5. Strategic Initiatives / Entropy
  • 10.8. SetPoint Medical Corporation
    • 10.8.1. Company Overview
    • 10.8.2. Company Snapshot
    • 10.8.3. Financial Overview
    • 10.8.4. Product Portfolio
    • 10.8.5. Strategic Initiatives / Entropy
  • 10.9. electroCore, Inc.
    • 10.9.1. Company Overview
    • 10.9.2. Company Snapshot
    • 10.9.3. Financial Overview
    • 10.9.4. Product Portfolio
    • 10.9.5. Strategic Initiatives / Entropy
  • 10.10. Saluda Medical Pty Ltd
    • 10.10.1. Company Overview
    • 10.10.2. Company Snapshot
    • 10.10.3. Financial Overview
    • 10.10.4. Product Portfolio
    • 10.10.5. Strategic Initiatives / Entropy

For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies where relevant to the market assessment.

11. KOL Views

12. Project Approach

13. About DelveInsight

14. Disclaimer and Contact Us

List of Tables

  • Table 1: Global Bioelectronic Medicine Market Size in USD million (2023-2034)
  • Table 2: Global Bioelectronic Medicine Market Size by Product in USD million (2023-2034)
  • Table 3: Global Bioelectronic Medicine Market Size by Application in USD million (2023-2034)
  • Table 4: Global Bioelectronic Medicine Market Size by End-Users in USD million (2023-2034)
  • Table 5: Global Bioelectronic Medicine Market Size by Geography in USD million (2023-2034)
  • Table 6: Bioelectronic Medicine Market Size in North America in USD million (2023-2034)
  • Table 7: Bioelectronic Medicine Market Size in the United States in USD million (2023-2034)
  • Table 8: Bioelectronic Medicine Market Size in Canada in USD million (2023-2034)
  • Table 9: Bioelectronic Medicine Market Size in Mexico in USD million (2023-2034)
  • Table 10: Bioelectronic Medicine Market Size in Europe in USD million (2023-2034)
  • Table 11: Bioelectronic Medicine Market Size in Germany in USD million (2023-2034)
  • Table 12: Bioelectronic Medicine Market Size in the United Kingdom in USD million (2023-2034)
  • Table 13: Bioelectronic Medicine Market Size in France in USD million (2023-2034)
  • Table 14: Bioelectronic Medicine Market Size in Italy in USD million (2023-2034)
  • Table 15: Bioelectronic Medicine Market Size in Spain in USD million (2023-2034)
  • Table 16: Bioelectronic Medicine Market Size in the Rest of Europe in USD million (2023-2034)
  • Table 17: Bioelectronic Medicine Market Size in Asia-Pacific in USD million (2023-2034)
  • Table 18: Bioelectronic Medicine Market Size in China in USD million (2023-2034)
  • Table 19: Bioelectronic Medicine Market Size in Japan in USD million (2023-2034)
  • Table 20: Bioelectronic Medicine Market Size in India in USD million (2023-2034)
  • Table 21: Bioelectronic Medicine Market Size in Australia in USD million (2023-2034)
  • Table 22: Bioelectronic Medicine Market Size in South Korea in USD million (2023-2034)
  • Table 23: Bioelectronic Medicine Market Size in the Rest of Asia-Pacific in USD million (2023-2034)
  • Table 24: Bioelectronic Medicine Market Size in the Rest of the World in USD million (2023-2034)
  • Table 25: Bioelectronic Medicine Market Size in the Middle East in USD million (2023-2034)
  • Table 26: Bioelectronic Medicine Market Size in Africa in USD million (2023-2034)
  • Table 27: Bioelectronic Medicine Market Size in South America in USD million (2023-2034)
  • Table 28: Bioelectronic Medicine Market Competitive Landscape
  • Table 29: Bioelectronic Medicine Market Startup Funding and Investment Trends

List of Figures

  • Figure 1: Bioelectronic Medicine Market Drivers
  • Figure 2: Bioelectronic Medicine Market Restraints
  • Figure 3: Bioelectronic Medicine Market Opportunities
  • Figure 4: Impact Analysis: AI, Geopolitical, Trade, and Economic Developments
  • Figure 5: Regulatory Analysis of the Bioelectronic Medicine Market (the United States)
  • Figure 6: Regulatory Analysis of the Bioelectronic Medicine Market (Europe)
  • Figure 7: Regulatory Analysis of the Bioelectronic Medicine Market (Japan)
  • Figure 8: Regulatory Analysis of the Bioelectronic Medicine Market (China)
  • Figure 9: Porter's Five Forces Analysis of the Bioelectronic Medicine Market
  • Figure 10: Competitive Analysis of the Bioelectronic Medicine Market
  • Figure 11: Global Bioelectronic Medicine Market Size in USD million (2023-2034)
  • Figure 12: Global Bioelectronic Medicine Market Size by Product in USD million (2023-2034)
  • Figure 13: Global Bioelectronic Medicine Market Size by Application in USD million (2023-2034)
  • Figure 14: Global Bioelectronic Medicine Market Size by End-Users in USD million (2023-2034)
  • Figure 15: Global Bioelectronic Medicine Market Size by Geography in USD million (2023-2034)
  • Figure 16: Bioelectronic Medicine Market Size in North America in USD million (2023-2034)
  • Figure 17: Bioelectronic Medicine Market Size in the United States in USD million (2023-2034)
  • Figure 18: Bioelectronic Medicine Market Size in Canada in USD million (2023-2034)
  • Figure 19: Bioelectronic Medicine Market Size in Mexico in USD million (2023-2034)
  • Figure 20: Bioelectronic Medicine Market Size in Europe in USD million (2023-2034)
  • Figure 21: Bioelectronic Medicine Market Size in Germany in USD million (2023-2034)
  • Figure 22: Bioelectronic Medicine Market Size in the United Kingdom in USD million (2023-2034)
  • Figure 23: Bioelectronic Medicine Market Size in France in USD million (2023-2034)
  • Figure 24: Bioelectronic Medicine Market Size in Italy in USD million (2023-2034)
  • Figure 25: Bioelectronic Medicine Market Size in Spain in USD million (2023-2034)
  • Figure 26: Bioelectronic Medicine Market Size in the Rest of Europe in USD million (2023-2034)
  • Figure 27: Bioelectronic Medicine Market Size in Asia-Pacific in USD million (2023-2034)
  • Figure 28: Bioelectronic Medicine Market Size in China in USD million (2023-2034)
  • Figure 29: Bioelectronic Medicine Market Size in Japan in USD million (2023-2034)
  • Figure 30: Bioelectronic Medicine Market Size in India in USD million (2023-2034)
  • Figure 31: Bioelectronic Medicine Market Size in Australia in USD million (2023-2034)
  • Figure 32: Bioelectronic Medicine Market Size in South Korea in USD million (2023-2034)
  • Figure 33: Bioelectronic Medicine Market Size in the Rest of Asia-Pacific in USD million (2023-2034)
  • Figure 34: Bioelectronic Medicine Market Size in the Rest of the World in USD million (2023-2034)
  • Figure 35: Bioelectronic Medicine Market Size in the Middle East in USD million (2023-2034)
  • Figure 36: Bioelectronic Medicine Market Size in Africa in USD million (2023-2034)
  • Figure 37: Bioelectronic Medicine Market Size in South America in USD million (2023-2034)